Core Viewpoint - A securities class action lawsuit has been filed against Firefly Aerospace Inc. by Kessler Topaz Meltzer & Check, LLP, alleging that the company made false and misleading statements regarding its business operations and growth prospects [1][2]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased Firefly's common stock during the IPO on August 7, 2025, and those who acquired securities between August 7, 2025, and September 29, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for January 12, 2026 [1]. Allegations Against Defendants - The complaint claims that Firefly overstated the demand and growth prospects for its Spacecraft Solutions offerings [2]. - It is alleged that the Alpha rocket program did not meet its claimed operational readiness and commercial viability [2]. - As a result of these issues, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [2]. Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline of January 12, 2026, or may choose to remain absent [3]. - The lead plaintiff will represent all class members in directing the litigation and selecting counsel [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5].

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1]. Company Overview - Soleno Therapeutics announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets on March 26, 2025, for treating hyperphagia in individuals aged 4 and older with Prader-Willi syndrome [3]. Recent Developments - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of VYKAT XR due to adverse effects was approximately 8% at the end of Q3 2025. The CEO acknowledged a disruption in the product's launch trajectory following a short seller report in mid-August, which led to a decrease in start forms and an increase in discontinuations for non-serious adverse events. Following this announcement, Soleno's share price dropped by over 26% [4].

Accessibility StatementSkip Navigation WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025Â to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the pas ...

Core Points - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud affecting investors between February 18, 2025, and July 31, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Fluor Corporation made false statements regarding the costs associated with its infrastructure projects, including Gordie Howe, I-635/LBJ, and I-35, which were reportedly increasing due to subcontractor design errors, price hikes, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a significant negative impact on the Company's business and financial results [3]. - The complaint further asserts that Fluor's financial guidance for FY 2025 was unreliable, the effectiveness of its risk mitigation strategy was overstated, and the impact of economic uncertainty was understated [3]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges and competition, leading to a loss of market share [2]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing it to macroeconomic uncertainty and weaker new business, partly due to ongoing restructuring within WPP Media (GroupM) [2]. - Following the trading update, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Avantor, Inc. for alleged securities fraud affecting investors between March 5, 2024, and October 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that Avantor's competitive positioning was misrepresented, indicating it was weaker than publicly stated [2]. - It is claimed that Avantor faced negative impacts from increased competition, which were not disclosed [2]. - The lawsuit asserts that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 29, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as a leading firm in securities litigation [4]. - The firm has been ranked in the Top 50 Report by ISS Securities Class Action Services for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2]. - It is alleged that the defendants misled investors about KBR's business operations and prospects, which were materially false and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 7, 2024, and September 12, 2025 [1][2] - The lawsuit claims that aTyr provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr dropped significantly by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Class Action Details - Investors who suffered losses during the specified timeframe can request to be appointed as lead plaintiff by December 8, 2025 [3] - Participation in the class action does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the accuracy of its reported demand for Prestige fragrances and actual retailer inventory levels [1][3]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products [3]. - Prestige fragrances represent 60% of Coty's revenues, indicating a significant reliance on this segment for financial performance [3]. Group 2: Investigation Details - The investigation is prompted by discrepancies between Coty's claims of strong Prestige fragrance demand and the reality of overstocked retailer inventories due to declining product demand [3]. - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as retailer inventory buildup and execution weaknesses in the U.S. market [4]. Group 3: Stock Performance - Following the release of disappointing financial results, Coty's stock price fell by $1.05 per share, a decline of over 21%, from $4.86 on August 20, 2025, to $3.81 on August 21, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of Q3 2025 financial results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The decline was attributed to customers requiring more customization for IP components, which negatively impacted the economics of the Design IP business [5][6].